Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in PCNSL
NCT00003505Phase 2Withdrawn
- Sponsor
- Burzynski Research Institute
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antineoplaston A10 and antineoplaston AS2-1 in primary central nervous system lymphoma (PCNSL), sponsored by Burzynski Research Institute. Primary endpoints: Safety and Side Effects at 12 months and Tumor Response at 2 years. Status: withdrawn.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT00003505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003505.